Literature DB >> 6770693

Nodular glomerulopathy associated with nonamyloidotic kappa light chain deposits and excess immunoglobulin light chain synthesis.

G R Gallo, H D Feiner, L A Katz, G M Feldman, E B Correa, J V Chuba, J N Buxbaum.   

Abstract

A nodular glomerulopathy characterized by mesangial deposits of monoclonal kappa light chains was detected by immunofluorescence in a renal biopsy from a patient with proteinuria and hypertension. These nodules lacked the tinctorial and morphologic features of amyloid. Ultrastructurally, the nodules contained electron-dense granular deposits as well as fibrils in parallel arrangement. The fibrils measured 110-140 A in diameter. They were consistent in size with amyloid fibrils. However, they differed in lacking the randomly oriented network of typical amyloid fibrils and more closely resembled fibrils intrinsic to mesangial matrix. The patient had no bone marrow or X-ray evidence of myeloma and no evidence of free monoclonal light chains in serum or concentrated urines. Biosynthetic studies of the patient's bone marrow cells demonstrated unbalanced immunoglobulin synthesis with excess production of monoclonal kappa light chains. These observations suggest that the observed glomerulopathy results from direct deposition of monoclonal light chains. Deposits with kappa light chain determinants have been found in 7 other patients with similar nodular glomerulopathies, 4 of whom had diagnosed clinical myeloma. The lesion of nonamyloidotic nodular glomerulopathy previously described in 19 patients, nor examined by immunopathologic techniques or not shown to contain light chain determinants, may have a similar pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6770693      PMCID: PMC1903701     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  21 in total

1.  Light-chain disease. An abortive variant of multiple myeloma.

Authors:  R C Williams; R D Brunning; F A Wollheim
Journal:  Ann Intern Med       Date:  1966-09       Impact factor: 25.391

Review 2.  Current concepts of amyloid.

Authors:  E C Franklin; D Zucker-Franklin
Journal:  Adv Immunol       Date:  1972       Impact factor: 3.543

3.  Multiple myeloma with urinary excretion of heavy chain components of IgG and nodular glomerulosclerosis.

Authors:  K Solling; S A Askjaer
Journal:  Acta Med Scand       Date:  1973 Jul-Aug

4.  Mesangial thickening and nodular glomerular sclerosis in diabetes mellitus and other diseases.

Authors:  S Olsen
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1972

5.  Polymer formation during the degradation of human light chain and Bence-Jones proteins by an extrct of the lysosomal fraction of normal human kidney.

Authors:  M Tan; W Epstein
Journal:  Immunochemistry       Date:  1972-01

6.  Creation of "amyloid" fibrils from Bence Jones proteins in vitro.

Authors:  G G Glenner; D Ein; E D Eanes; H A Bladen; W Terry; D L Page
Journal:  Science       Date:  1971-11-12       Impact factor: 47.728

7.  Biologic and clinical significance of cryoglobulins. A report of 86 cases.

Authors:  J C Brouet; J P Clauvel; F Danon; M Klein; M Seligmann
Journal:  Am J Med       Date:  1974-11       Impact factor: 4.965

8.  The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments.

Authors:  R D Wochner; W Strober; T A Waldmann
Journal:  J Exp Med       Date:  1967-08-01       Impact factor: 14.307

9.  Glomerular nodules and long-spacing collagen in kidneys of patients with multiple myeloma.

Authors:  G E Schubert; A Adam
Journal:  J Clin Pathol       Date:  1974-10       Impact factor: 3.411

10.  Synthesis and assembly of immunoglobulins by malignant human plasmacytes. I. Myelomas producing gamma-chains and light chains.

Authors:  S Zolla; J Buxbaum; E C Franklin; M D Scharff
Journal:  J Exp Med       Date:  1970-07-01       Impact factor: 14.307

View more
  19 in total

1.  Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture.

Authors:  J Buxbaum
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

2.  Renal and systemic kappa light chain deposits and their plasma cell origin identified by immunoelectron microscopy.

Authors:  M M Silver; S A Hearn; S Ritchie; R P Slinger; J A Sholdice; P S Cordy; A B Hodsman
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

3.  Systemic lambda light-chain deposition presenting with predominant cardiac involvement.

Authors:  M J Garton; S Walton; S W Ewen
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

Review 4.  Renal lesions in dysproteinemias.

Authors:  P Verroust; L Morel-Maroger; J L Preud'Homme
Journal:  Springer Semin Immunopathol       Date:  1982

5.  Charge of circulating immune complexes as a factor in glomerular basement membrane localization in mice.

Authors:  G R Gallo; T Caulin-Glaser; M E Lamm
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

6.  Acute renal failure with polyarteritis nodosa and multiple myeloma.

Authors:  A J Williams; A C Newland; F P Marsh
Journal:  Postgrad Med J       Date:  1985-05       Impact factor: 2.401

7.  Primary cardiovascular amyloidosis with benign monoclonal gammopathy.

Authors:  L Pajor; G Kelényi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

Review 8.  Nonamyloidotic fibrillary glomerulopathy. Report of a case and review of the literature.

Authors:  A Billis; E Homsi
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

9.  Significance of fibrils in the formation of the Kimmelstiel-Wilson nodule.

Authors:  T Yasuda; H Imai; Y Nakamoto; A B Miura; S Inomata
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

10.  [Successful treatment of kappa light chain nephropathy using membrane plasma separation].

Authors:  K B Sprenger; J Galle; I Sprenger-Klasen; J M Herrmann; H E Franz
Journal:  Klin Wochenschr       Date:  1984-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.